Targeting costimulatory molecules to improve antitumor immunity.
J Biomed Biotechnol
; 2012: 926321, 2012.
Article
en En
| MEDLINE
| ID: mdl-22500111
ABSTRACT
The full activation of T cells necessitates the concomitant activation of two signals, the engagement of T-cell receptor by peptide/major histocompatibility complex II and an additional signal delivered by costimulatory molecules. The best characterized costimulatory molecules belong to B7/CD28 and TNF/TNFR families and play crucial roles in the modulation of immune response and improvement of antitumor immunity. Unfortunately, tumors often generate an immunosuppressive microenvironment, where T-cell response is attenuated by the lack of costimulatory molecules on the surface of cancer cells. Thus, targeting costimulatory pathways represent an attractive therapeutic strategy to enhance the antitumor immunity in several human cancers. Here, latest therapeutic approaches targeting costimulatory molecules will be described.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Receptores de Antígenos de Linfocitos T
/
Linfocitos T
/
Antígenos CD28
/
Antígenos B7
/
Neoplasias
Límite:
Animals
/
Humans
Idioma:
En
Revista:
J Biomed Biotechnol
Asunto de la revista:
BIOTECNOLOGIA
/
MEDICINA
Año:
2012
Tipo del documento:
Article
País de afiliación:
Italia